Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Current Therapeutic Research-clinical and Experimental Pub Date : 2023-10-28 DOI:10.1016/j.curtheres.2023.100723

Reza Abniki MS , Amirhossein Tashakor MS , Melika Masoudi PhD , Davood Mansury PhD

{"title":"Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis","authors":"Reza Abniki MS , Amirhossein Tashakor MS , Melika Masoudi PhD , Davood Mansury PhD","doi":"10.1016/j.curtheres.2023.100723","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Relebactam, previously known as MK-7655, is currently being tested in combination with imipenem as a class A and class C β-lactamase inhibitor, including KPC from <em>Klebsiella pneumoniae</em>.</p></div><div><h3>Objective</h3><p>The objective of the current study was to evaluate the activity of imipenem/relebactam against gram-negative bacilli.</p></div><div><h3>Methods</h3><p>After applying exclusion and inclusion criteria, 72 articles with full texts that describe the prevalence of imipenem/relebactam resistance were chosen for the meta-analysis and systematic review. Articles published between January 2015 and February 2023 were surveyed. The systematic literature search was conducted in PubMed, Web of Science, Google Scholar, and Scopus.</p></div><div><h3>Results</h3><p>The pooled estimation of 282,621 sample isolates revealed that the prevalence rate of imipenem/relebactam resistance is roughly 14.6% (95% CI, 0.116%–0.182%).</p></div><div><h3>Conclusions</h3><p>The findings of this analysis show that imipenem/relebactam resistance is rare in the majority of developed countries. Given that relebactam has proven to restore the activity of imipenem against current clinical isolates, further research into imipenem/relebactam is necessary.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100723"},"PeriodicalIF":1.6000,"publicationDate":"2023-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X23000322/pdfft?md5=4a99ef11eb23e0a423d533ad9cd718f3&pid=1-s2.0-S0011393X23000322-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X23000322","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Relebactam, previously known as MK-7655, is currently being tested in combination with imipenem as a class A and class C β-lactamase inhibitor, including KPC from Klebsiella pneumoniae.

Objective

The objective of the current study was to evaluate the activity of imipenem/relebactam against gram-negative bacilli.

Methods

After applying exclusion and inclusion criteria, 72 articles with full texts that describe the prevalence of imipenem/relebactam resistance were chosen for the meta-analysis and systematic review. Articles published between January 2015 and February 2023 were surveyed. The systematic literature search was conducted in PubMed, Web of Science, Google Scholar, and Scopus.

Results

The pooled estimation of 282,621 sample isolates revealed that the prevalence rate of imipenem/relebactam resistance is roughly 14.6% (95% CI, 0.116%–0.182%).

Conclusions

The findings of this analysis show that imipenem/relebactam resistance is rare in the majority of developed countries. Given that relebactam has proven to restore the activity of imipenem against current clinical isolates, further research into imipenem/relebactam is necessary.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

亚胺培南/雷贝拉坦对革兰氏阴性杆菌的全球耐药性：系统回顾和元分析

背景雷巴坦（以前称为 MK-7655）作为一种 A 类和 C 类 β-内酰胺酶抑制剂，目前正在与亚胺培南联用进行测试，其中包括肺炎克雷伯菌中的 KPC。方法在应用排除和纳入标准后，荟萃分析和系统综述选择了 72 篇全文描述亚胺培南/雷巴坦耐药性流行情况的文章。调查对象为 2015 年 1 月至 2023 年 2 月间发表的文章。结果对 282,621 份样本分离物的汇总估算显示，亚胺培南/瑞巴坦耐药率约为 14.6%（95% CI，0.116%-0.182%）。鉴于雷巴坦已被证明可恢复亚胺培南对当前临床分离菌株的活性，因此有必要对亚胺培南/雷巴坦进行进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.